CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event

Rhea-AI Summary

Tevogen Bio Holdings, a clinical-stage immunotherapy firm (Nasdaq: TVGN), held its inaugural post-public listing social engagement on May 31, 2024. The event, attended by elected officials, first responders, and U.S. Congress members, aimed to discuss the company's innovative business model and treatments using CD8+ cytotoxic T lymphocytes for diseases like cancer and neurological disorders. The gathering included mayors from various NJ towns, U.S. Congressmen Josh Gottheimer and Robert Menendez, and first responders like Matthew Caliente and Robert Ferreiro. CEO Dr. Ryan Saadi emphasized the societal value of Tevogen's business model and thanked attendees, particularly the patients who shared their experiences.

Positive

• Tevogen Bio is developing advanced T cell therapies for infectious diseases, cancers, and neurological disorders.
• The company is founded by industry leaders with significant drug development and global product launch experience.
• Tevogen's business model aims to reduce healthcare costs and improve patient outcomes.
• The event was attended by prominent figures including mayors and U.S. Congress members, indicating strong societal interest.
• CEO Dr. Ryan Saadi highlighted the link between sustainable business success and societal prosperity.

Negative

• The press release lacks specific financial data and upcoming milestones, making it challenging to gauge immediate investor impact.
• No concrete timelines or results for the clinical trials involving CD8+ CTLs were provided.
• The PR does not mention any recent revenue figures or changes in financial status post-public listing.

WARREN, N.J., June 07, 2024 (GLOBE NEWSWIRE) -- A release was issued under a similar headline on Thursday, June 6^th by Tevogen Bio Holdings Inc. (Nasdaq: TVGN). Please note that the second paragraph has been corrected and a photo is now included. The corrected release follows:

Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes (“CD8+ CTLs”), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders with the aim of addressing the significant unmet needs of large patient populations.

Tevogen Bio, founded by a group of pioneering industry leaders and distinguished scientists with extensive drug development and global product launch experience, aims to chart the next frontier of medicine, where disruptive science and innovative business models pave the way to a healthier future for all, centered on the concept that sustainable business success is intrinsically linked to societal prosperity. At its inaugural post-public listing social engagement on May 31, 2024, Tevogen's leadership gathered with Victor Sordillo (Mayor, Warren Twp. NJ), Lisa Lontai (Deputy Mayor, Warren Twp. NJ), Raymond Giacobbe (Mayor, Rahway NJ), Matthew Moench (Mayor, Bridgewater NJ), Andrew McNally (Mayor, Bernards NJ), Robert Parisi (Former Mayor, West Orange NJ), Tammy Williams (Councilwoman, West Orange NJ), Sara Sooy (Commissioner Deputy Director, Somerset County NJ), Douglas Singleterry (Commissioner of Somerset County), and Honorable U.S. Congressmen Josh Gottheimer and Robert Menendez. The event also included the nation’s first responders including Matthew Caliente (President of Professional Firefighters Association of New Jersey and Long COVID patient advocate) and Robert Ferreiro (Warren Twp. Chief of Police) aiming to understand patients' needs and discuss how the Tevogen model could reduce healthcare costs and improve patient outcomes.

"We are honored by the widespread interest in Tevogen's business model from all sectors of society and express our gratitude to all attendees, especially the patients who shared their stories," remarked Dr. Ryan Saadi, founding CEO of Tevogen Bio.

About Tevogen Bio

Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and twelve pending patents, two of which are related to artificial intelligence.

Contacts

Tevogen Bio Communications
T: 1-877-TEVOGEN, Ext-701
Communications@Tevogen.com

Photo: https://www.globenewswire.com/NewsRoom/AttachmentNg/3acdaab4-dbc7-4635-8017-47fa52389a44

FAQ

What is Tevogen Bio's stock symbol?

Tevogen Bio's stock symbol is TVGN.

When was Tevogen Bio's inaugural post-public listing social event?

Tevogen Bio's inaugural post-public listing social event was held on May 31, 2024.

What diseases is Tevogen Bio targeting with its CD8+ T cell therapies?

Tevogen Bio is targeting infectious diseases, cancers, and neurological disorders with its CD8+ T cell therapies.

Who attended Tevogen Bio's social engagement event?

The event was attended by elected officials, U.S. Congress members, first responders, and patients.

What is the focus of Tevogen Bio's business model?

Tevogen Bio's business model focuses on reducing healthcare costs and improving patient outcomes.